Search

Your search keyword '"Dreyfus, Brigitte"' showing total 23 results
Start Over Author "Dreyfus, Brigitte" Publication Year Range Last 10 years
23 results on '"Dreyfus, Brigitte"'

1. Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial

Author

Herling, Carmen D., Cymbalista, Florence, Groß-Ophoff-Müller, Carolin, Bahlo, Jasmin, Robrecht, Sandra, Langerbeins, Petra, Fink, Anna-Maria, Al-Sawaf, Othman, Busch, Raymonde, Porcher, Raphael, Cazin, Bruno, Dreyfus, Brigitte, Ibach, Stefan, Leprêtre, Stéphane, Fischer, Kirsten, Kaiser, Florian, Eichhorst, Barbara, Wentner, Clemens-Martin, Hoechstetter, Manuela A., Döhner, Hartmut, Leblond, Veronique, Kneba, Michael, Letestu, Remi, Böttcher, Sebastian, Stilgenbauer, Stephan, Hallek, Michael, and Levy, Vincent

Published
2020
Full Text
View/download PDF

2. Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients

Author

Österborg, Anders, Wierda, William G., Mayer, Jiří, Hess, Georg, Hillmen, Peter, Schetelig, Johannes, Schuh, Anna, Smolej, Lukáš, Beck, Christian, Dreyfus, Brigitte, Hellman, Andrzej, Kozlowski, Piotr, Pfreundschuh, Michael, Rizzi, Rita, Spacek, Martin, Phillips, Jennifer L., Gupta, Ira V., Williams, Vanessa, Jewell, Roxanne C., Nebot, Noelia, Lisby, Steen, and Dyer, Martin J. S.

Published
2015
Full Text
View/download PDF

3. Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia

Author

Letestu, Rémi, Dahmani, Abdelmalek, Boubaya, Marouane, Baseggio, Lucile, Campos, Lydia, Chatelain, Bernard, Debliquis, Agathe, Drénou, Bernard, Jacob, Marie-Christine, Legac, Eric, Le Garff-Tavernier, Magali, Lhoumeau, Anne-Catherine, Quiney, Claire, Robillard, Nelly, Ticchioni, Michel, Aanei, Carmen, Katsahian, Sandrine, Delepine, Roselyne, Vaudaux, Sandrine, Rouillé, Valérie, Béné, Marie-Christine, Dartigeas, Caroline, Van Den Neste, Eric, Leprêtre, Stéphane, Feugier, Pierre, Cartron, Guillaume, Leblond, Véronique, Lévy, Vincent, Cymbalista, Florence, Cailleres, Sylvie, Damaj, Gandhi, Royer, Bruno, Gardembas, Martine, Dib, Mamoun, Truchan-Graczyk, Matgorzata, Hunault, Mathilde, Foussard, Charles, Corront, Bernadette, Parry, Anne, Orsini-Piocelle, Frédérique, Trouillier, Sébastien, Slama, Bohiane, Lepeu, Gérard, Zerazhi, Hacene, Boulat, Olivier, Azzedine, Ahmed, Araujo, Carla, Banos, Anne, Bauduer, Frédéric, Dutel, Jean-Luc, Ghomari, Kamel, Deconinck, Eric, Brion, Annie, Vuillier, Jacqueline, Saad, Alain, El Yamani, Abderrazak, Rodon, Philippe, Soubeyran, Pierre, Etienne, Gabriel, Dilhuydy, Marie-Sarah, Bouabdallah, Krimo, Leguay, Thibaut, Chouffi, Bachra, Pollet, Bertrand, Maakaroun, Abdallah, Guillerm, Gaëlle, Berthou, Christian, Cheron, Nathalie, ANDRÉ, Marc, Vilque, Jean Pierre, Fruchart, Christophe, Voillat, Laurent, Pica, Gian Matteo, Corm, Sélim, Micléa, Jean-Michel, Souleau, Bertrand, Molucon-Chabrot, Cécile, De Renzis, Benoit, Tournilhac, Olivier, Bay, Jacques-Olivier, Chaleteix, Carine, Guieze, Romain, Fleury, Joel, Precupanu, Cristina, Bouledroua, Selwa, Haiat, Stéphanie, Petitdidier, Charlotte, Dupuis, Jehan, Belhadj, Karim, Casasnovas, Olivier, Bastie, Jean-Noel, Ferrant, Emmanuelle, Gholam, Dany, Molina, Lysiane, Garban, Frédéric, Tiab, Mourad, Maisonneuve, Hervé, Villemagne, Bruno, Jacomy, Dominique, Besson, Caroline, Tertian, Gérard, Laribi, Kamel, Morel, Pierre, Cazin, Bruno, Moreau, Stéphane, Reminieras, Liliane, Rapp, Marie-José, Moreau, Philippe, Sebban, Catherine, Michallet, Anne-Sophie, Salles, Gilles, Broussais, Florence, Aurran-Schleinitz, Thérèse, Coso, Diane, Abarah, Wajed, Kulekci, Claire, Dorvaux, Véronique, Carassou, Philippe, Guibaud, Isabelle, Christian, Bernard, Graux, Carlos, Rossi, Jean-François, Quittet, Philippe, Dubois, Alain, Eisenmann, Jean-Claude, Morineau, Nadine, Mahé, Béatrice, Karsenti, Jean-Michel, Jourdan, Eric, Legouffe, Eric, Alexis-Vigier, Magda, Boulet, Jean-Michel, Aoudjhane, Malek, Thiéblemont, Catherine, Andreoli, Anna Lisa, Dreyfus, François, Choquet, Sylvain, Maloum, Karim, Merle-Béral, Hélène, Vekhoff, Anne, Decaudin, Didier, Brault, Philippe, Delarue, Richard, Janvier, Maud, Soussain, Carole, Vallantin, Xavier, Sanhes, Laurence, Dreyfus, Brigitte, Tomowiak, Cécile, Benramdane, Riad, Gonzalez, Hugo, Blaise-Brenna, Anne, Kolb, Brigitte, Delmer, Alain, Dauriac, Charles, Houot, Roch, Escoffre-Barbe, Martine, Lamy, Thierry, De Guibert, Sophie, Bernard, Marc, Grosbois, Bernard, Brehar, Oana, Morice, Patrick, Guyotat, Denis, Jaubert, Jérome, Portois, Christelle, Fornecker, Luc-Matthieu, Herbrecht, Raoul, Bilger, Karin, Ame, Shanti, Ysebaert, Loic, Godmer, Pascal, Jardel, Henry, Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), CHU Saint-Etienne, CHU UCL Namur, Groupe hospitalier de la région de Mulhouse Sud-Alsace (GHRMSA), CHU Grenoble, Centre Hospitalier Régional d'Orléans (CHRO), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Universitaire de Nice (CHU Nice), Hopital Saint-Louis [AP-HP] (AP-HP), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université Catholique de Louvain = Catholic University of Louvain (UCL), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Université de Montpellier (UM), UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - (MGD) Laboratoire de biologie clinique, UCL - (SLuc) Service d'hématologie, Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)

Subjects
0301 basic medicine, Male, Cancer Research, Neoplasm, Residual, MESH: Immunotherapy, Chronic lymphocytic leukemia, Gastroenterology, MESH: Clinical Trials, Phase III as Topic, 0302 clinical medicine, Bone Marrow, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, MESH: Leukemia, Lymphocytic, Chronic, B-Cell, MESH: Aged, education.field_of_study, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Hematology, MESH: Follow-Up Studies, Prognosis, 3. Good health, Fludarabine, Survival Rate, Leukemia, MESH: Antineoplastic Combined Chemotherapy Protocols, medicine.anatomical_structure, Oncology, 030220 oncology & carcinogenesis, MESH: Vidarabine, MESH: Bone Marrow, Female, MESH: Rituximab, Immunotherapy, Rituximab, MESH: Clinical Trials, Phase II as Topic, Vidarabine, medicine.drug, medicine.medical_specialty, Cyclophosphamide, MESH: Survival Rate, Population, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH: Prognosis, 03 medical and health sciences, Clinical Trials, Phase II as Topic, Chemoimmunotherapy, Internal medicine, medicine, Humans, education, Survival rate, MESH: Neoplasm, Residual, Aged, Retrospective Studies, MESH: Humans, business.industry, MESH: Cyclophosphamide, MESH: Retrospective Studies, medicine.disease, Leukemia, Lymphocytic, Chronic, B-Cell, MESH: Male, body regions, 030104 developmental biology, Clinical Trials, Phase III as Topic, Bone marrow, business, MESH: Female, Follow-Up Studies
Abstract

International audience; Measurable residual disease (MRD) status is widely adopted in clinical trials in patients with chronic lymphocytic leukemia (CLL). Findings from FILO group trials (CLL2007FMP, CLL2007SA, CLL2010FMP) enabled investigation of the prognostic value of high-sensitivity (0.7 × 10-5) MRD assessment using flow cytometry, in blood (N = 401) and bone marrow (N = 339), after fludarabine, cyclophosphamide, and rituximab (FCR)-based chemoimmunotherapy in a homogeneous population with long follow-up (median 49.5 months). Addition of low-level positive MRD

Published
2020
Full Text
View/download PDF

4. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib

Author

Ghez, David, Calleja, Anne, Protin, Caroline, Baron, Marine, Ledoux, Marie-Pierre, Damaj, Gandhi, Dupont, Mathieu, Dreyfus, Brigitte, Ferrant, Emmanuelle, Herbaux, Charles, Laribi, Kamel, Le Calloch, Ronan, Malphettes, Marion, Paul, Franciane, Souchet, Laetitia, Truchan-Graczyk, Malgorzata, Delavigne, Karen, Dartigeas, Caroline, Ysebaert, Loïc, and on behalf on the French Innovative Leukemia Organization (FILO) CLL group

Published
2018
Full Text
View/download PDF

5. Open Label Non-Randomized Phase II Study Exploring «Chemo-Free » Treatment Association with Idelalisib + Obinutuzumab in Patients with Relapsed/Refractory (R/R) Waldenstrom's Macroglobulinemia (MW), a Filo Trial: Results of the Intermediary Analysis of the Induction Phase

Author

Tomowiak, Cecile, primary, Desseaux, Kristell, primary, Poulain, Stéphanie, primary, Herbaux, Charles, primary, Perrot, Aurore, primary, Mahe, Beatrice, primary, Morel, Pierre, primary, Tournilhac, Olivier, primary, Lepretre, Stephane, primary, Aurran, Thérèse, primary, Villemagne, Bruno, primary, Casasnovas, Olivier, primary, Nollet, Delphine, primary, Dreyfus, Brigitte, primary, Chevret, Sylvie, primary, and Leblond, Veronique, primary

Published
2019
Full Text
View/download PDF

7. Oral CHOP‐like chemotherapy in 60–80 years‐old patients with diffuse large B‐cell lymphoma

Author

Guidez, Stephanie, primary, Lacotte‐Thierry, Laurence, additional, Tomowiak, Cecile, additional, Princet, Isabelle, additional, Dreyfus, Brigitte, additional, Olivier, Gaelle, additional, Fleck, Emmanuel, additional, Corby, Anne, additional, Motard, Carine, additional, Barrier, Jocelyn, additional, Machet, Antoine, additional, Le Dû, Katell, additional, Debiais‐Delpech, Celine, additional, Chabin, Michele, additional, Leleu, Xavier, additional, Guilhot, Joëlle, additional, and Delwail, Vincent, additional

Published
2019
Full Text
View/download PDF

8. Characterisation of a new clinical presentation of chronic lymphocytic leukaemia: symptomatic bronchial involvement, a study from the FILO group

Author

Nudel, Morgane, primary, Baran‐Marszak, Fanny, additional, Bossard, Jean‐Baptiste, additional, Dubois, Romain, additional, Dapvril, Héloïse, additional, Dupuis, Jehan, additional, Laribi, Kamel, additional, Bay, Jacques‐Olivier, additional, Tomowiak, Cécile, additional, Dreyfus, Brigitte, additional, Lepretre, Stéphane, additional, Demarquette, Hélène, additional, Wallyn, Frédéric, additional, Wemeau, Lidwine, additional, Wemeau, Mathieu, additional, Poulain, Stéphanie, additional, Morschhauser, Franck, additional, Cymbalista, Florence, additional, and Herbaux, Charles, additional

Published
2019
Full Text
View/download PDF

9. p53 Functional Assessment and Correlation with 17p Deletion and/or TP53 Mutation Status: Final Report of the ICLL001 Bomp Trial

Author

Le Garff-Tavernier, Magali, primary, Quiney, Claire, additional, Veronese, Lauren, additional, Nguyen-Khac, Florence, additional, Robbe, Pauline, additional, Combes, Patricia, additional, Dilhuydy, Marie-Sarah, additional, Feugier, Pierre, additional, Mahe, Beatrice, additional, Sanhes, Laurence, additional, Delmer, Alain Jacques, additional, Ysebaert, Loic, additional, Truchan-Graczyk, Malgorzata, additional, Dreyfus, Brigitte, additional, Sylvain, Choquet, additional, Aurran, Thérèse, additional, Ferrant, Emmanuelle, additional, Dartigeas, Caroline, additional, Leprêtre, Stéphane, additional, Pica, Gian Matteo, additional, Davi, Frederic, additional, Pereira, Bruno, additional, Delepine, Roselyne, additional, Schuh, Anna, additional, Guieze, Romain, additional, Bay, Jacques-Olivier, additional, Leblond, Véronique, additional, Merle-Beral, Helene, additional, de Guibert, Sophie, additional, and Tournilhac, Olivier, additional

Published
2018
Full Text
View/download PDF

10. Oral CHOP-like Chemotherapy in Elderly Patients with High-Grade Non Hodgkin B Cell Lymphoma

Author

Guidez, Stephanie, primary, Tomowiak, Cecile, additional, Princet, Isabelle, additional, Dreyfus, Brigitte, additional, Olivier, Gaelle, additional, Fleck, Emmanuel, additional, Corby, Anne, additional, Motard, Carine, additional, Machet, Antoine, additional, Debiais, Celine, additional, Leleu, Xavier, additional, Guilhot, Joelle, additional, and Delwail, Vincent, additional

Published
2018
Full Text
View/download PDF

13. Relapsed chronic lymphocytic leukemia retreated with rituximab: interim results of the PERLE study

Author

Chaoui, Driss, primary, Choquet, Sylvain, additional, Sanhes, Laurence, additional, Mahé, Béatrice, additional, Hacini, Maya, additional, Fitoussi, Olivier, additional, Arkam, Yazid, additional, Orfeuvre, Hubert, additional, Dilhuydy, Marie-Sarah, additional, Barry, Marly, additional, Jourdan, Eric, additional, Dreyfus, Brigitte, additional, Tempescul, Adrian, additional, Leprêtre, Stéphane, additional, Bardet, Aurélie, additional, Leconte, Pierre, additional, Maynadié, Marc, additional, and Delmer, Alain, additional

Published
2017
Full Text
View/download PDF

15. Relapsed or refractory chronic lymphocytic leukemia retreated with rituximab in daily practice: final results of the PERLE study.

Author

Chaoui, Driss, Leprêtre, Stéphane, Liu, Kun Lun, Barry, Marly, Tempescul, Adrian, Dilhuydy, Marie-Sarah, Chaib, Abdelaziz, Slama, Borhane, Labourey, Jean Luc, Benbrahim, Omar, Dreyfus, Brigitte, Hacini, Maya, Mahé, Béatrice, Maynadié, Marc, Delmer, Alain, Benkanoun, Chahinez, Boissard, Frédéric, Gandon, Sophie, Veerabudun, Kalaivani, and Choquet, Sylvain

Subjects
CHRONIC lymphocytic leukemia, PROGRESSION-free survival
Published
2019
Full Text
View/download PDF

16. A phase II Bayesian sequential clinical trial in advanced Waldenström macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasone.

Author

Leblond, Véronique, Morel, Pierre, Dilhuidy, Marie-Sarah, Leleu, Xavier, Soussain, Carole, Leprête, Stéphane, Dreyfus, Brigitte, Dartigeas, Caroline, Mahé, Béatrice, Anglaret, Bruno, Pégourié, Brigitte, Besson, Caroline, Aurran, Thérèse, Vekhoff, Anne, Tournilhac, Olivier, Banos, Anne, Oya, Hervé, Lejeune, Julie, Ouzegdouh, Maya, and Chevret, Sylvie

Subjects
WALDENSTROM'S macroglobulinemia, BORTEZOMIB, DEXAMETHASONE, RITUXIMAB, COMBINATION drug therapy, PROGRESSION-free survival, CLINICAL drug trials, THERAPEUTICS
Abstract

n patients with advanced Waldenström macroglobulinemia (WM), overall response rate (ORR) and median progression-free survival (PFS) achieved with bortezomib alone and bortezomib rituximab combination were 27–85% and 7.9 months, and 81% and 16.4 months, respectively. We checked the role of dexamethasone in combination with bortezomib by enrolling in a phase II trial 34 patients with relapsed/refractory WM. Bortezomib (1.3 mg/m2 IV D1, 4, 8, and 11 every 21 days) was used for six cycles. In non-responding patients, dexamethasone (20 mg daily for two days) was added to each infusion after the second cycle. After two cycles, the Bayes estimated ORR was 43.2 (95% Credible Interval: 28.0–59.1%) using the informative prior. Two-year survival rate was 84.0% and the median PFS 15.3 months without difference between patients treated with or without dexamethasone. We conclude that dexamethasone must be associated to bortezomib-based regimen. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

18. Bendamustine, Ofatumumab and High-Dose Methylprednisolone (BOMP) in Relapsed/Refractory CLL: Results of a Planned Interim Analysis of the French CLL Intergroup ICLL01 Phase II Trial

Author

de Guibert, Sophie, primary, Dilhuydy, Marie-Sarah, additional, Ysebaert, Loic, additional, Sanhès, Laurence, additional, Choquet, Sylvain, additional, Aurran-Schleinitz, Therese, additional, Guieze, Romain, additional, Mahe, Beatrice, additional, Daguindau, Nicolas, additional, Araujo, Carla, additional, Saad, Hussam, additional, Ferrant, Emmanuelle, additional, Cazin, Bruno, additional, Feugier, Pierre, additional, Dreyfus, Brigitte, additional, Alain, Delmer, additional, Lepretre, Stéphane, additional, Le Garff-Tavernier, Magali, additional, Lauren, Véronese, additional, Schuh, Anna, additional, Pereira, Bruno, additional, Leblond, Veronique, additional, and Tournilhac, Olivier, additional

Published
2014
Full Text
View/download PDF

19. Use of Human Immunoglobulins in Secondary Immunodeficiencies Associated with Hematological Malignancy in Real-Life Practice: Which Patients, Which Treatment?

Author

Benbrahim, Omar, primary, Grosbois, Bernard, additional, Viallard, Jean-François, additional, Choquet, Sylvain, additional, Royer, Bruno, additional, Dreyfus, Brigitte, additional, Fleck, Emmanuel, additional, Carreiro, Miguel, additional, Clerson, Pierre, additional, Crave, Jean Charles, additional, Delain, Jean-christophe, additional, and Levy, Vincent, additional

Published
2014
Full Text
View/download PDF

22. p53 Functional Assessment and Correlation with 17p Deletion and/or TP53Mutation Status: Final Report of the ICLL001 Bomp Trial

Author

Le Garff-Tavernier, Magali, Quiney, Claire, Veronese, Lauren, Nguyen-Khac, Florence, Robbe, Pauline, Combes, Patricia, Dilhuydy, Marie-Sarah, Feugier, Pierre, Mahe, Beatrice, Sanhes, Laurence, Delmer, Alain Jacques, Ysebaert, Loic, Truchan-Graczyk, Malgorzata, Dreyfus, Brigitte, Sylvain, Choquet, Aurran, Thérèse, Ferrant, Emmanuelle, Dartigeas, Caroline, Leprêtre, Stéphane, Pica, Gian Matteo, Davi, Frederic, Pereira, Bruno, Delepine, Roselyne, Schuh, Anna, Guieze, Romain, Bay, Jacques-Olivier, Leblond, Véronique, Merle-Beral, Helene, de Guibert, Sophie, and Tournilhac, Olivier

Abstract

Introduction: The 17p deletion (del(17p)) resulting in loss of the TP53gene is associated with impaired response to genotoxic agents and has an impact on PFS following BTK inhibitor and possibly also venetoclax. The del(17p) usually coincides with TP53mutation, leading to the impairment of the p53-associated pathway. Sole TP53mutations appear also associated with poor outcome in prospective trials. The iwCLL guidelines recommend to look for del(17p) and TP53mutation before each line of treatment. An original approach is the functional assay, which highlights the functional abnormalities of p53 whether it is a TP53gene disruption (del(17p) and/or TP53mutation) or a defect of another actor in the p53 pathway. We aim to validate this functional assay on a prospective trial and to study the impact of p53 status on the clinical response regardless of the biological method.

Published
2018
Full Text
View/download PDF

23. Dynamic of Telomeric Parameters in Relapsing or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL), an Analysis of the Filo ICLL001 Bomp Trial

Author

Bounaix, Laura, Tchirkov, Andrei, Nguyen-Khac, Florence, Combes, Patricia, Feugier, Pierre, Sanhes, Laurence, Dilhuydy, Marie-Sarah, Saad, Hussam, Ysebaert, Loic, Sylvain, Choquet, Vilque, Jean-Pierre, Brion, Annie, Araujo, Carla, Ferrant, Emmanuelle, Dreyfus, Brigitte, Delmer, Alain Jacques, Truchan-Graczyk, Malgorzata, Leprêtre, Stéphane, de Guibert, Sophie, Guieze, Romain, Veronese, Lauren, Lemal, Richard, Vago, Philippe, Bay, Jacques-Olivier, Berger, Marc G., Schuh, Anna, Ferrand, Christophe, Delepine, Roselyne, Leblond, Véronique, and Tournilhac, Olivier

Abstract

Background.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results